Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Sequenom grosses $51.6 million for diagnostics development: Firm will gross $51.6 million through the sale of 12.4 million shares of its stock at $4.15 each to "certain investors" under an agreement announced May 12. The private placement is expected to close May 17. Proceeds will be used for R&D and product commercialization efforts. The San Diego firm says it expects launch a noninvasive, laboratory-developed DNA test for Down syndrome (Trisomy 21) by the end of 2011 and file a PMA application for the test by the end of 2012. Sequenom also is aiming to launch a laboratory-developed test for age-related macular degeneration in the first half of 2011. Jefferies & Company and Lazard Capital Markets were placement agents for the stock offering
You may also be interested in...
Robotic knee surgery
Curexo Technology submits 510(k) application for use of its Robodoc robotic surgical system to prepare knee joints for replacement. Robodoc allows surgeons to preoperatively plan total knee arthroplasty procedures in a 3-D virtual space and then perform the surgery exactly as planned on the patient's knee. The robotic surgical system gained 510(k) clearance for use in total hip arthroplasty in August and has been used in over 24,000 surgical procedures worldwide to date (1"The Gray Sheet" Aug. 25, 2008, In Brief)
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.